New Delhi: SRL Diagnostics on Monday announced the launch of new lab test ST2 to help predict risks of coronary heart disease by finding a specific biomarker in the bloodstream.
SRL claims to be the first diagnostic lab in India to have launched this key medical test, available across India at all Fortis Labs, SRL Diagnostics Labs and its collection centres.
Dr B R Das, president – research & innovation, SRL Diagnostics, said, “Unlike many other cardiac biomarkers, ST2 is faster thus helping physicians make informed decisions on an appropriate course of action to take and, if needed, to quickly adjust treatment. It can reduce 30-day rehospitalisation rates by 17.3 per cent and also reduce 30-day mortality rates by 17.6 per cent.”
Recent evidence has reported the incidence of cardiovascular disease (CVD) to be 40 to 50 per cent higher in Asian Indians than individuals of other ethnic origins. In addition, some 30 to 40 per cent of cardiovascular deaths occur between 35 and 64 years of age. The prevalence of heart failure in India due to coronary heart disease, hypertension, obesity, diabetes and rheumatic heart disease ranges from 1.3 million to 4.6 million, with an annual incidence of 4,91,600–1.8 million, according to a statement by SRL.
“ST2 is ELISA based test which is a US FDA approved technology and was included in 2013 ACC/AHA Guidelines for The Management of Heart Failure. It has been extensively evaluated with more than 100 peer-reviewed articles and scientific posters studying more than 35,000 patients. So far, SRL Diagnostics has collected 100 samples for predicting the heart failure,” Dr Das added.
The American College of Cardiology Foundation / American Heart Association Task Force jointly released its expanded clinical practice guideline for the management of patients with heart failure and has identified ST2 “not only predictive of hospitalization and death in patients with HF [heart failure] but also additive to natriuretic peptide levels in its prognostic value.